


## Supplementary material


**Table S1.** Specific primers for human transcripts used in this study.

Gene	Accession Number	Primer Sequence (Sense)	Primer Sequence (Antisense)	Product Size (bp)
<i>MKI67</i>	NM_002417	GACATCCGTATCCAGCTTCC T	GCCGTACAGGCTCATCAATA AC	139
<i>CDKN2D</i>	NM_001800.4	AACCGCTTCGGCAAGAC	GCTGGCACCTTGCTTCA	67
<i>MMP9</i>	NM_004994.2	CAGTGCCATGTAAATCCCC A	CACCTCCACTCCTCCCTTC	102
<i>PRPF40A</i>	NM_017892.3	GCTCGGAAGATGAAACGAA A	TGTCCTCAAATGCTGGCTCT	130
<i>AR-v7</i>	NM_001348061 .1	CAGGGATGACTCTGGGAAA A	TGAGGCAAGTCAGCCTTTCT	87
<i>SSTR5</i>	NM001053	CTGGTGTTCGCGGATGTT	GAAGCTCTGGCGGAAGTTGT	183
<i>SST5TMD4</i>	NM_001172560 .1	TACCTGCAACCGTCTGCC	AGCCTGGGCCTTTCTCCT	98
<i>In1-Ghrelin</i>	GU942497.1	TCTGGGCTTCAGTCTTCTCC	GTTTCATCCTCTGCCCCCTCT	215
<i>EZH2</i>	NM_004456.5	CACTCCTTTCATACGCTTTTC TG	TGTTTCTGTGTTCTTCCGCTT A	119
<i>CDK2</i>	NM_001798.4	GCTCTCACTGGCATTCTCT T	GAGGTTTAAGGTCTCGGTGG	109
<i>CDK4</i>	NM_000075.3	ACAGTTCGTGAGGTGGCTTT	TACCTTGATCTCCCGTCAG	111
<i>MMP3</i>	NM_002422.5	ACTAGCAAGGACCTCGTTTT CA	AGGGTGTGGATGCCTCTTG	79
<i>IL6-R</i>	NM_000565.4	AAGGCTGTGCTCTTGTTGAG	TGGGACTCCTGGAATACTG	83
<i>VEGFR</i>	NM_002253.3	TCTCTGCCTACCTCACCTGT TT	TGACTGATTCTGCTGTGTT G	89
<i>GPR107</i>	NM_001136557 .2	AACCAGACCCAGAAGACAC AA	GAACTGCCCCACCATTATT	109
<i>ACTB</i>	NM_001101	ACTCTCCAGCCTTCTTCTCT	CAGTGATCTCCTTCTGCATC CT	176
<i>GADPH</i>	NM_002046	AATCCCATCACCATCTTCCA	AAATGAGCCCCAGCCTTC	122


NCBI accession number, primers sequences and expected product sizes are included.



**Figure S1.** Validation (at mRNA and protein levels by qPCR and Western blot) of GPR107-silencing in androgen-independent PCa cell line 22Rv1 after 48 h of GPR107 siRNA transfection. mRNA levels of *GPR107* were determined by qPCR and adjusted by *ACTB* expression levels. GPR107 protein level was normalized by B-Tubulin (TUBB) protein levels. Data were represented as percent of scrambled cells (set at 100%). Asterisks (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ) indicate statistically significant differences between GPR107-silencing and scrambled cells.



**Figure S2.** Correlation between *GPR107* expression levels and different key oncogenic factors in primary PCa samples from patients with metastasis. Correlation of *GPR107* expression level and *SST5TMD4* (A), *SST5* (B), *In1-Ghrelin* (C) and *AR-v7* (D) expression in primary PCa samples from patients with metastasis (cohort 2). mRNA levels were determined by qPCR and adjusted by *ACTB* expression levels or by normalization factor (NF) generated by the combination of *ACTB* and *GAPDH* expression levels.



**Figure S3.** Comparison of *GPR107* expression levels between non-Tumoral (N), primary tumor (PT), mHSPC specimens (M) obtained from three in silico databases (Lapointe, Taylor and Tomlins). The Y-axis represents the Log2-normalized gene expression. An ANOVA test is performed in order to compare the mean gene expression among groups.